CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.

Chongqing Zhifei Biological Products Co., Ltd.

300122

CNE100000V20

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 2025-07-08			5-day change	1st Jan Change
19.85 ^CNY	+2.11%		+1.33%	-24.52%

Jun. 06	Zhifei Biological Products' Pneumonia Vaccine Enters Production Registration Review	MT
Jun. 03	Chinese Drug Regulator Accepts Chongqing Zhifei Biological Products' Application to Produce Meningococcal Vaccine	MT

Zhifei Biological Products' Pneumonia Vaccine Enters Production Registration Review

Published on 06/06/2025 at 02:32

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Chongqing Zhifei Biological Products Co., Ltd.

Zhifei Biological Products' Pneumonia Vaccine Enters Production Registration Review	Jun. 06	MT
Chinese Drug Regulator Accepts Chongqing Zhifei Biological Products' Application to Produce Meningococcal Vaccine	Jun. 03	MT
Zhifei Biological Products Falls to Q1 Loss as Revenue Falls 79%	Apr. 22	MT
Zhifei Biological Products' 2024 Profit Down 75%; Shares Fall 7%	Apr. 22	MT
Zhifei Biological Products Says 2024 Net Profit Down 75.0% Y/Y	Apr. 21	RE
Chongqing Zhifei Biological Products Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	Apr. 21	CI
Chongqing Zhifei Biological Products Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	Apr. 21	CI
Zhifei Biological To Boost Investment In Biopharma Firm	Mar. 21	RE
Chongqing Chenan Biopharmaceutical Co., Ltd. announced that it expects to receive CNY 593.265306 million in funding from Chongqing Zhifei Biological Products Co., Ltd.	Mar. 20	CI
Chongqing Zhifei Biological, GSK Adjust Terms of Cooperation Agreement	Dec. 09	MT
GSK, China's Zhifei Extend Shingles Shot Collaboration to 2034	Dec. 05	DJ
GSK expands deal with China's Zhifei to explore RSV vaccine collaboration	Dec. 05	RE
GSK plc and Zhifei Biological Products, Ltd Revise and Extend Strategic Vaccine Collaboration in China	Dec. 05	CI
Chongqing Zhifei Biological Products Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024	24-10-25	CI
Chongqing Zhifei Biological Products Co., Ltd. Approves Election of Zhang Xinrong as Independent Director	24-09-23	CI
Chongqing Zhifei Biological Products Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	24-08-29	CI
Zhifei Biological Products' Unit Launches Clinical Trials on Pneumonia Vaccine	24-08-21	MT
Chongqing Zhifei Biological Products' 2023 Profit Rises 7%; Shares Plunge 12%	24-04-23	MT
Chongqing Zhifei Biological Products Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	24-04-22	CI
Tranche Update on Chongqing Zhifei Biological Products Co., Ltd.'s Equity Buyback Plan announced on February 22, 2024.	24-03-28	CI
Chongqing Zhifei Biological Products Co., Ltd.'s Equity Buyback announced on February 22, 2024, has closed with 6,210,253 shares, for CNY 300.01 million.	24-03-27	CI
Chongqing Zhifei Biological Products Co., Ltd. announces an Equity Buyback for CNY 500 million worth of its shares.	24-02-22	CI
Chongqing Zhifei Biological Products Co., Ltd. authorizes a Buyback Plan.	24-02-21	CI
Zhifei Biological Falls After Merck Secures Nod to Market HPV Vaccine in China	24-01-10	MT
Zhifei Biological Products to Acquire Local Biopharma Firm, Expanding Into Metabolic Disease Treatments	23-11-27	MT

Chart Chongqing Zhifei Biological Products Co., Ltd.

Duration

Period

Chart Chongqing Zhifei Biological Products Co., Ltd.

300122: Dynamic Chart

Chongqing Zhifei Biological Products Co., Ltd. specializes in the research and development of vaccines for human use. The products include, in particular, bacterial vaccines for the prevention of meningitis, tuberculosis, rabies and influenza.

Employees

7,220

Sector

Pharmaceuticals

Calendar

Jul. 13 - Extraordinary Shareholders Meeting

More about the company